<DOC>
	<DOCNO>NCT00000950</DOCNO>
	<brief_summary>The purpose study determine relationship exist level antituberculosis drug ( isoniazid , rifampin , ethambutol , pyrazinamide ) blood outcome HIV-positive patient tuberculosis . This study also evaluate drug absorb metabolize body .</brief_summary>
	<brief_title>Metabolism Antituberculosis Drugs HIV-Infected Persons With Tuberculosis</brief_title>
	<detailed_description>Patients receive 8 week two anti-tuberculosis drug , least two isoniazid , rifampin , pyrazinamide , ethambutol . Blood specimen collect 2 , 6 , 10 hour administration study medication , Days 10 14 phase daily treatment intermittent dose regimen ( twice weekly three time weekly ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Antitubercular Agents</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive tuberculosis . Are 13 year age old . Have write , informed consent parent guardian 18 year age . Agree practice abstinence use barrier method birth control study . Exclusion Criteria You eligible study : Have disorder condition might cause study treatment undesirable . Are pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Isoniazid</keyword>
	<keyword>Pyrazinamide</keyword>
	<keyword>Pyridoxine</keyword>
	<keyword>Rifampin</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Ethambutol</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antitubercular Agents</keyword>
</DOC>